Metastatic melanoma-specific delivery of MEK inhibitors can be achieved by targeting overexpressed EphA2 receptors in vemurafenib-sensitive cells using nanosized EphA2-targeted PEGylated liposomes. The gene discussed is MAP2K7; the disease is melanoma.